INTRODUCTION:Telephone tobacco quitlines are effective and are widely used, with more than 500,000 U.S. callers in 2010. This study investigated the clinical effectiveness and cost-effectiveness of 3 different quitline enhancements: combination nicotine replacement therapy (NRT), longer duration of NRT, and counseling to increase NRT adherence. METHODS: In this study, 987 quitline callers were randomized to a combination of quitline treatments in a 2 × 2 × 2 factorial design: NRT duration (2 vs. 6 weeks), NRT type (nicotine patch only vs. patch plus nicotine gum), and standard 4-call counseling (SC) versus SC plus medication adherence counseling (MAC). The primary outcome was 7-day point-prevalence abstinence (PPA) at 6 months postquit in intention-to-treat (ITT) analyses. RESULTS:Combination NRT for 6 weeks yielded the highest 6-month PPA rate (51.6%) compared with 2 weeks of nicotine patch (38.4%), odds ratios [OR] = 1.71 (95% confidence interval [CI]:1.20-2.45). A similar result was found for 2 weeks of combination NRT (48.2%), OR = 1.49 (95% CI: 1.04-2.14) but not for 6 weeks of nicotine patch alone (46.2%), OR = 1.38 (95% CI: 0.96-1.97). The MAC intervention effect was nonsignificant. Cost analyses showed that the 2-week combination NRT group had the lowest cost per quit ($442 vs. $464 for 2-week patch only, $505 for 6-week patch only, and $675 for 6-week combination NRT). CONCLUSIONS:Combination NRT for 2 or 6 weeks increased 6-month abstinence rates by 10% and 13%, respectively, over rates produced by 2 weeks of nicotine patch when offered with quitline counseling. A 10% improvement would potentially yield an additional 50,000 quitters annually, assuming 500,000 callers to U.S. quitlines per year.
RCT Entities:
INTRODUCTION: Telephone tobacco quitlines are effective and are widely used, with more than 500,000 U.S. callers in 2010. This study investigated the clinical effectiveness and cost-effectiveness of 3 different quitline enhancements: combination nicotine replacement therapy (NRT), longer duration of NRT, and counseling to increase NRT adherence. METHODS: In this study, 987 quitline callers were randomized to a combination of quitline treatments in a 2 × 2 × 2 factorial design: NRT duration (2 vs. 6 weeks), NRT type (nicotine patch only vs. patch plus nicotine gum), and standard 4-call counseling (SC) versus SC plus medication adherence counseling (MAC). The primary outcome was 7-day point-prevalence abstinence (PPA) at 6 months postquit in intention-to-treat (ITT) analyses. RESULTS: Combination NRT for 6 weeks yielded the highest 6-month PPA rate (51.6%) compared with 2 weeks of nicotine patch (38.4%), odds ratios [OR] = 1.71 (95% confidence interval [CI]:1.20-2.45). A similar result was found for 2 weeks of combination NRT (48.2%), OR = 1.49 (95% CI: 1.04-2.14) but not for 6 weeks of nicotine patch alone (46.2%), OR = 1.38 (95% CI: 0.96-1.97). The MAC intervention effect was nonsignificant. Cost analyses showed that the 2-week combination NRT group had the lowest cost per quit ($442 vs. $464 for 2-week patch only, $505 for 6-week patch only, and $675 for 6-week combination NRT). CONCLUSIONS: Combination NRT for 2 or 6 weeks increased 6-month abstinence rates by 10% and 13%, respectively, over rates produced by 2 weeks of nicotine patch when offered with quitline counseling. A 10% improvement would potentially yield an additional 50,000 quitters annually, assuming 500,000 callers to U.S. quitlines per year.
Authors: S M Hall; K L Delucchi; W F Velicer; C W Kahler; J Ranger-Moore; D Hedeker; J Y Tsoh; R Niaura Journal: Nicotine Tob Res Date: 2001-08 Impact factor: 4.244
Authors: Shu-Hong Zhu; Christopher M Anderson; Gary J Tedeschi; Bradley Rosbrook; Cynthia E Johnson; Michael Byrd; Elsa Gutiérrez-Terrell Journal: N Engl J Med Date: 2002-10-03 Impact factor: 91.245
Authors: Tai-Hing Lam; Abu Saleh M Abdullah; Sophia S C Chan; Anthony J Hedley Journal: Psychopharmacology (Berl) Date: 2004-07-29 Impact factor: 4.530
Authors: Andrew Hyland; Qiang Li; Joseph E Bauer; Gary A Giovino; Craig Steger; K Michael Cummings Journal: Nicotine Tob Res Date: 2004-12 Impact factor: 4.244
Authors: Louise C W Wiggers; Ellen M A Smets; Frans J Oort; Marja N Storm-Versloot; Hester Vermeulen; Lucas B M van Loenen; Ron J G Peters; Hanneke C J M de Haes; Dink A Legemate Journal: Int J Behav Med Date: 2006
Authors: Megan E Piper; Jessica W Cook; Tanya R Schlam; Douglas E Jorenby; Stevens S Smith; Linda M Collins; Robin Mermelstein; David Fraser; Michael C Fiore; Timothy B Baker Journal: Ann Behav Med Date: 2018-09-13
Authors: Nayoung Kim; Danielle E McCarthy; Wei-Yin Loh; Jessica W Cook; Megan E Piper; Tanya R Schlam; Timothy B Baker Journal: Drug Alcohol Depend Date: 2019-10-25 Impact factor: 4.492
Authors: Bianca F Jardin; Karen L Cropsey; Amy E Wahlquist; Kevin M Gray; Gerard A Silvestri; K Michael Cummings; Matthew J Carpenter Journal: Nicotine Tob Res Date: 2014-03-07 Impact factor: 4.244
Authors: Tanya R Schlam; Jessica W Cook; Timothy B Baker; Todd Hayes-Birchler; Daniel M Bolt; Stevens S Smith; Michael C Fiore; Megan E Piper Journal: Psychopharmacology (Berl) Date: 2018-04-25 Impact factor: 4.530
Authors: Tanya R Schlam; Michael C Fiore; Stevens S Smith; David Fraser; Daniel M Bolt; Linda M Collins; Robin Mermelstein; Megan E Piper; Jessica W Cook; Douglas E Jorenby; Wei-Yin Loh; Timothy B Baker Journal: Addiction Date: 2015-11-19 Impact factor: 6.526